All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the most promising new targetable pathway in CLL?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What is the most promising new targetable pathway in chronic lymphocytic leukemia?

What is the most promising new targetable pathway in CLL?

Danilov begins by highlighting that preclinical studies are currently focusing on several targets, such as B-cell receptor pathways and Bruton's tyrosine kinase inhibitors, which are close to entering everyday clinical practice. Cell apoptosis also remains a promising target with multiple novel agents being investigated further, such as those targeting Bcl-X. Finally he discusses the promise of immunotherapy such as CAR T-cell therapy and bispecific antibodies.

 

Share: